Patent 7439330 was granted and assigned to President and Fellows of Harvard College on October, 2008 by the United States Patent and Trademark Office.
The invention includes antibodies or antigen-binding fragments thereof which bind specifically to glycated CD59, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of producing and using the antibodies or antigen-binding fragments thereof for diagnosis and treatment of diabetic conditions and diabetic-associated conditions.